Why the study?
Do low-molecular-weight heparins prevent venous thromboembolism in patients with cancer?
Population
Patients with cancer, particularly those undergoing surgical operation, chemotherapy, or venous…
Comparison
Low-molecular-weight heparins (LMWHs) vs Standard heparin
Design
Review
Authors
Loading...
Should not yet change VTE prophylaxis practice in cancer; leaves open survival effects pending randomized data.
Do low-molecular-weight heparins prevent venous thromboembolism in patients with cancer?
Low-molecular-weight heparins are a promising, safer alternative to standard heparin for thromboprophylaxis in cancer patients, with potential additional survival benefits.
Kakkar et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: